Skip to content

Benefits and safety of high flow nasal oxygen in mild to moderate acute hypoxemic respiratory failure at medical ward, a randomized trial

Benefits and safety of high flow nasal oxygen in mild to moderate acute hypoxemic respiratory failure at medical ward, a randomized trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20180130001
Enrollment
60
Registered
2018-01-30
Start date
2018-01-30
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult inpatients who were admitted in medical general wards with the diagnosis mild to moderate acute hypoxia. high flow nasal oxygen&#44

Interventions

Standard Oxygen supplementation via nasal cannula.,HFNO system consists of nasal cannula&#44
heated inspiratory circuit&#44
humidifier&#44
oxygen blender and flow meter. Gas from air&#45
oxygen blender is humidified and heated before given to patient.
Active Comparator Device,Active Comparator Device
standard oxygen therapy ,High&#45

Sponsors

no
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 0 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: all the following 1. Mild to moderate acute hypoxemic respiratory failure(table) 2. Admitted at general medical wards 3. Age >18 years old Definition of mild to moderate hypoxemic respiratory failure • Respiratory rate >25 breaths/min and/or increased work of breathing, evidenced by clinical signs (dyspnea, use of accessory muscles of respiration, diaphoresis) AND • Requiring >4 L/min O2 via nasal cannula or requiring O2 therapy equivalent to FiO2 >0.4 to keep PaO2 >60 mmHg or SpO2 >90% for >1 hour

Exclusion criteria

Exclusion criteria: 1. PaCO2 >45 mmHg 2. Post-extubation respiratory failure (respiratory failure within 48 hr after extubation) 3. Life-threatening ARF requiring immediate IMV 4. Shock 5. Contraindications to NIV 6. A do-not-intubate order 7. Patients refused to participate the study 8. Intra-abdominal hypertension 9. Pulmonary tuberculosis

Design outcomes

Primary

MeasureTime frame
Rate of required NIV or IMV within 48 hours after randomization within 48 hours after randomization Number of subject who need NIV or IMV initiation within 48 hours after randomization

Secondary

MeasureTime frame
30-day mortality 30 day Number of subject died at 30 day after randomization

Contacts

Public ContactChalerm Liwsrisakun

Chiang Mai University

chalermliw@hotmail.com0818813880

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026